5 minute read
Jul. 27, 2022

Biotechnology-Based Molecules in Oncology: 2021 IPO Review Pt. IV

drughunter.com
Drug Hunter Team

This short article and poster summary takes a deeper look into the 2021 IPOs for biotechnology-based therapeutics being developed by oncology-focused companies, including:

  • Antibody-drug conjugates

  • Monoclonal antibodies

  • Protein-based therapeutics

  • Cell and gene therapies

  • Other biotechnology-based therapeutics

This article is Part 4 of a review series covering all of the initial public offerings for the biotech and pharmaceutical industries in 2021. Part 1 and Part 2 provided an overview of 2021 IPOs by therapy area, technology, and therapeutic class. Part 3 provided a deep dive into the 2021 IPOs for oncology-focused companies developing conventional small molecule therapeutics. 

Loading...

twitterlinkedinemail

Other articles you may be interested in